Lazertinib is a Small Molecule owned by Genosco, and is involved in 21 clinical trials, of which 7 were completed, 9 are ongoing, and 5 are planned.

Lazertinib elicits activity by blocking T790M mutated EGFR receptor. The mutation activates wild type EGFR and the introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant. The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance. By blocking mutated receptor, the drug candidates possess therapeutic potential in drug resistant non small cell lung cancer.

The revenue for Lazertinib is expected to reach a total of $1.7bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Lazertinib NPV Report.

Lazertinib is originated and owned by Genosco. Johnson & Johnson is the other company associated in development or marketing of Lazertinib.

Lazertinib Overview

Lazertinib mesylate (Leclaza) is an oral, third-generation, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) acts as anti neoplastic agent. It is formulated as film coated tablets for oral route of administration. Leclaza is indicated for the treatment of patients with EGFR T790M mutation-positive locally advanced or metastatic non-small cell lung cancer previously treated with EGFR-TKI.

Lazertinib is under development for the treatment of non small cell lung cancer and metastatic brain cancer. The drug candidate targets T790M and L858M mutated EGFR. It is administered through oral route.

Johnson & Johnson Overview

Johnson & Johnson (J&J) researches, develops, manufactures, and sells pharmaceutical products, medical devices, and consumer products. The company provides pharmaceuticals for immune diseases, cancer, neurological disorders, infectious, cardiovascular and metabolic diseases; consumer products in oral care, baby care, beauty, over-the-counter (OTC) medicines, women’s health and wound care categories; and medical devices for use in the cardiovascular, orthopaedic, general surgery and vision care fields. J&J distributes pharmaceutical and medical products to retailers, wholesalers, health care professionals and hospitals; and offers consumer products through retail outlets and distributors. The company offers its products in the US; Europe; Asia-Pacific and Africa; and Western Hemisphere (excluding the US). J&J is headquartered in New Brunswick, New Jersey, the US.

The company reported revenues of (US Dollars) US$93,775 million for the fiscal year ended January 2021 (FY2021), an increase of 13.6% over FY2020. In FY2021, the company’s operating margin was 24.3%, compared to an operating margin of 20% in FY2020. In FY2021, the company recorded a net margin of 22.3%, compared to a net margin of 17.8% in FY2020. The company reported revenues of US$23,791 million for the third quarter ended October 2022, a decrease of 1% over the previous quarter.

Quick View – Lazertinib

Report Segments
  • Innovator (NME)
Drug Name
  • Lazertinib
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.